Drug trial aims to rescue failing transplants
NCT ID NCT03948529
Summary
This study tested if a drug called eltrombopag could help patients whose blood cell counts remained dangerously low after a stem cell transplant for leukemia, a condition known as poor graft function. The goal was to see if the drug could boost platelet, red blood cell, and white blood cell counts, reducing the need for transfusions and improving quality of life. The trial was small and ended early, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
Conditions
Explore the condition pages connected to this study.